General form of registration statement for all companies including face-amount certificate companies

Note 20 - Revision of Prior Period Financial Statements - Revised Consolidated Financial Statements (Details)

v3.24.3
Note 20 - Revision of Prior Period Financial Statements - Revised Consolidated Financial Statements (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Accrued liabilities $ 973   $ 973   $ 1,902 $ 855  
Total current liabilities 2,413   2,413   2,532 2,361  
Total liabilities 2,413   2,413   2,532 2,361  
Accumulated deficit (79,010)   (79,010)   (76,624) (74,021)  
Total shareholders’ deficit (1,215) $ (1,729) (1,215) $ (1,729) 109 (2,226) $ (3,014)
Research and development expenses 350 199 639 320 741 1,299  
General and administration expenses 626 399 1,191 696 2,196 1,542  
Total operating expenses 1,269 769 2,372 1,320 3,576 3,444  
Loss before Income Tax (1,264) (323) (2,386) (876) (2,602) (3,904)  
Net (loss) income $ (1,264) $ (323) (2,386) (876) (2,603) (3,904)  
Change in accrued liabilities     (929) 176 1,047 97  
Net cash used in operating activities     $ (2,418) $ (936) $ (2,172) (2,892)  
Previously Reported [Member]              
Accrued liabilities           740  
Total current liabilities           2,246  
Total liabilities           2,246  
Accumulated deficit           (73,906)  
Total shareholders’ deficit           (2,111)  
Research and development expenses           1,272  
General and administration expenses           1,454  
Total operating expenses           3,329  
Loss before Income Tax           (3,789)  
Net (loss) income           (3,789)  
Change in accrued liabilities           (18)  
Net cash used in operating activities           (2,892)  
Revision of Prior Period, Adjustment [Member]              
Accrued liabilities           115  
Total current liabilities           115  
Total liabilities           115  
Accumulated deficit           (115)  
Total shareholders’ deficit           (115)  
Research and development expenses           27  
General and administration expenses           88  
Total operating expenses           115  
Loss before Income Tax           (115)  
Net (loss) income           (115)  
Change in accrued liabilities           115  
Net cash used in operating activities           $ 0